(Q51904511)

English

The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation.

scientific article published in October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

follicular lymphoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

10

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Stephen H Petersdorf

6

object named as

Stephen H Petersdorf

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

David G. Maloney

7

object named as

David G Maloney

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

author name string

Grant E Keeney

1

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Ted A Gooley

2

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Rosalyn N Pham

3

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

John M Pagel

5

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

William Bensinger

8

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Leona Holmberg

9

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

48

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

10

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

1961-1967

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

The epidemiology of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Relationship between haemoglobin and haematocrit in the definition of anaemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583983

21 January 2018

Identifiers

10.1080/10428190701583983

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 April 2018

http://europepmc.org/abstract/MED/17917964

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51904511&oldid=1521636835"